Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease
Status:
Withdrawn
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to characterize the acute anti-dyskinetic properties of
intravenous levetiracetam in Parkinson's disease patients who have been optimized on
antiparkinsonian medication. The secondary objective is to study the effect of intravenous
LEV on additional motor and cognitive symptoms of PD.